VWWMG
MDGL icon

Vermillion & White Wealth Management Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vermillion & White Wealth Management Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14
Closed -$8.15K – 339
2025
Q4 		$8.15K Hold
14
– – ﹤0.01% 339
2025
Q3 		$6.42K Hold
14
– – ﹤0.01% 378
2025
Q2 		$4.24K Buy
+14
New +$4.17K ﹤0.01% 406

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vermillion & White Wealth Management Group's MDGL Position: Q1 2026 in Review

Vermillion & White Wealth Management Group sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 14 shares — an estimated $8.15K sold.

Vermillion & White Wealth Management Group first reported a position in MDGL in Q2 2025 and held it in 3 quarters. The position peaked at $8.15K in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Vermillion & White Wealth Management Group reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Vermillion & White Wealth Management Group sold 14 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $8.15K.
  • Vermillion & White Wealth Management Group first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Vermillion & White Wealth Management Group's Madrigal Pharmaceuticals position peaked at $8.15K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Vermillion & White Wealth Management Group's 13F filing for Q1 2026, filed 14 May 2026.